|Last Price||Today's Change||52-Week Range||Trading Volume|
|0.90||0.00 (0.00%)||0.69 - 1.60||0.0|
Market data as of 12:00AM 11/12/14. Quotes are delayed by at least 15 min.
BioTime’s Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
11/03/2014 7:00 AM ET